Search results
Results from the WOW.Com Content Network
Prostate cancer screening is the screening process used to detect undiagnosed prostate cancer in men without signs or symptoms. [ 1 ] [ 2 ] When abnormal prostate tissue or cancer is found early, it may be easier to treat and cure, but it is unclear if early detection reduces mortality rates.
"In fact, prevention and screening interventions accounted for eight out of 10 deaths averted," co-lead investigator Katrina A. B. Goddard, Ph.D., director of NCI’s Division of Cancer Control ...
Regadenoson, sold under the brand name Lexiscan among others, is an A 2A adenosine receptor agonist that is a coronary vasodilator that is commonly used in pharmacologic stress testing. It produces hyperemia quickly and maintains it for a duration that is useful for radionuclide myocardial perfusion imaging . [ 1 ]
The consequences of overdiagnosis and overtreatment resulting from cancer screening can lead to a decline in quality of life, due to the adverse effects of unnecessary medication and hospitalization. [10] [12] [13] The accuracy of a cancer screening test relies on its sensitivity, and low sensitivity screening tests can overlook cancers. [10]
Patients are typically offered testing if they have either a personal or family history of cancer that meets certain criteria, Zakalik adds. Those criteria have broadened over the last few years ...
In a separate study of men from the pre prostate cancer screening era managed with watchful waiting (56% over age 70 years), progression to distant metastasis or prostate cancer death was 13.9% and 12.3%, respectively for Gleason score 6 or below, but considerably higher at 18.2 and 22.7%, 30% and 20%, 44.4% and 55.6% for Gleason 3+4, 4+3, and ...
Black men in the U.S., Khanna said, are two times more likely to die from prostate cancer than white men. “Not all prostate cancer is lethal, but we have seen that black men do have a higher ...
In men aged 55–69 who have been counseled on the known harms and potential benefits of prostate cancer screening, the U.S. Preventive Service Task Force May 2018 statement states, "The use of digital rectal examination as a screening modality is not recommended because there is a lack of evidence on the benefits."